(EXAS competition)—FDA approves Epigenomics’ “Epi proColon” blood test for colorectal cancer: http://www.epigenomics.com/en/news-investors/news-media/press-releases/latest-news/article/epigenomics-erhaelt-fda-zulassung-fuer-epi-procolonR.html This was the FDA’s third review of Epi proColon following CRLs in Nov 2015 (#msg-118279184) and Jun 2014 (#msg-102836984). Epigenomics (ECX.DE, EPGNF) is +24% today.